Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc develops cancer medicines based on its proprietary ProTide technology, with news centered on the ADR-listed clinical-stage biopharmaceutical company’s oncology pipeline and corporate updates. Recurring releases describe NUC-7738, a novel anti-cancer agent being studied as a monotherapy in advanced solid tumors and with pembrolizumab in melanoma, and NUC-3373, a 5-fluorouracil-derived new chemical entity being studied with pembrolizumab and docetaxel in advanced solid tumors and lung cancer.
Company updates also cover clinical and translational data presentations, patent protection for NUC-7738, quarterly and annual financial results, cash runway commentary, executive and board changes, and Nasdaq continued-listing matters for NuCana’s American depositary shares.
NuCana plc (NASDAQ: NCNA) has resumed patient enrollment in its global Phase III study, NuTide:121, for Acelarin combined with cisplatin in treating biliary tract cancer. Enrollment is re-opened in regions including Australia, Canada, South Korea, Taiwan, Ukraine, and the UK. The ongoing COVID-19 pandemic has impacted global healthcare, making this study's resumption critical for patient treatment. The trial aims to enroll up to 828 patients across about 120 sites worldwide, comparing Acelarin and cisplatin against the standard gemcitabine plus cisplatin regimen.